HFA 2024 — Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) sat down with Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss insights from the STEP-HFpEF programme.

STEP HFpEF aimed to test the hypothesis that treatment with semaglutide can improve symptoms in patients with HFpEF and obesity. This discussion centers around the background of the primary results of STEP-HFpEF, specifically in terms of the patients' NTproBNP levels. This study analysed both the effect of semaglutide on NTproBNP, as well as the effect of semaglutide on the primary and secondary endpoints of STEP-HFpEF according to patients' baseline NTproBNP.

Findings showed that all patients regardless of NTproBNP benefited from semaglutide as compared to placebo, both in terms of improvement in KCCQ Clinical Summary Score, and weight loss. However, patients at higher NTproBNP levels had greater improvement in KCCQ score than those with lower NTproBNP.

Recorded onsite at HFA 24, Lisbon.

Support: This is an independent discussion produced by Radcliffe Cardiology.

Editor: Mirjam Boros, Jordan Rance
Video Specialist: Tom Green, Oliver Miles